Roche shared a post on LinkedIn:
“We are pleased to announce the appointment of Mark Dawson as Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. He will also become a member of Roche’s Enlarged Corporate Executive Committee.
Mark brings deep expertise in oncology research and translational science. His academic and clinical background spans medicine, research, and innovation, with an M.D. from the University of Melbourne and a PhD from the University of Cambridge. As Head of Roche Pharma Research and Early Development (pRED), Mark will lead our efforts to advance breakthrough science into transformative medicines for patients worldwide.”
Peter MacCallum Cancer Centre shared a post by Roche, adding:
“Congratulations to Professor Mark Dawson on his appointment as Head of Roche Pharma Research and Early Development.
This prestigious appointment reflects Professor Dawson’s groundbreaking career achievements and demonstrates the rich depth of talent that Peter Mac helps foster and develop.
A globally recognized leader, award-winning researcher, and generous mentor, his contributions to cancer biology, particularly in chromatin regulation and epigenetics, have shaped our understanding of the molecular mechanisms driving cancer and enabled the development of first-in-class epigenetic therapies now being translated into clinical trials worldwide.
Professor Dawson’s vision, collaborative spirit and scientific excellence continue to inspire those around him, and we wish him every success as he brings his passion and energy to this next chapter of his illustrious career.
We’re also pleased that he will continue an association with Peter Mac and the University of Melbourne.”
Other articles featuring Mark Dawson on OncoDaily.